Literature DB >> 15624567

Amantadine in pediatric patients with traumatic brain injury: a retrospective, case-controlled study.

Liza B Green1, Joseph E Hornyak, Edward A Hurvitz.   

Abstract

OBJECTIVE: To determine if amantadine use in pediatric patients with traumatic brain injury is well tolerated and to attempt to assess its effectiveness.
DESIGN: This was a retrospective, case-controlled study.
RESULTS: Of the 54 patients, aged 3-18 yrs, who were administered amantadine, five (9%) had side effects that might have been related to the drug. These included hallucinations, delusions, increased aggression, and nausea/vomiting. The side effects were reversed when the medication was stopped or the dosage decreased. Patients in the amantadine group had a greater increase in Ranchos Los Amigos level during their admission than those in the control group (median, 3 vs. 2; P < 0.01). This difference may be, at least in part, explained by the fact that the amantadine group started at a lower Ranchos Los Amigos level (median, 3 vs. 4; P < 0.01). There were subjective improvements noted in 29 of the 46 patients (63%) in the amantadine group whose full charts were available for review.
CONCLUSION: Amantadine is a well tolerated medication when it is used in pediatric patients with traumatic brain injury. Subjective improvements were noted in the majority of the patients administered amantadine, and the amantadine group showed a greater improvement in Ranchos Los Amigos level during admission, suggesting that it may be effective.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15624567     DOI: 10.1097/01.phm.0000143400.15346.c8

Source DB:  PubMed          Journal:  Am J Phys Med Rehabil        ISSN: 0894-9115            Impact factor:   2.159


  12 in total

Review 1.  Medical therapies for concussion.

Authors:  William P Meehan
Journal:  Clin Sports Med       Date:  2011-01       Impact factor: 2.182

Review 2.  The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder.

Authors:  Ke Wu; Gregory L Hanna; David R Rosenberg; Paul D Arnold
Journal:  Pharmacol Biochem Behav       Date:  2011-10-15       Impact factor: 3.533

3.  Amantadine: a review of use in child and adolescent psychiatry.

Authors:  Sheik Hosenbocus; Raj Chahal
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2013-02

4.  A Narrative Review of Pharmacologic and Non-pharmacologic Interventions for Disorders of Consciousness Following Brain Injury in the Pediatric Population.

Authors:  Nathan K Evanson; Andrea L Paulson; Brad G Kurowski
Journal:  Curr Phys Med Rehabil Rep       Date:  2016-02-17

Review 5.  Pediatric Traumatic Brain Injury and Autism: Elucidating Shared Mechanisms.

Authors:  Rahul Singh; Ryan C Turner; Linda Nguyen; Kartik Motwani; Michelle Swatek; Brandon P Lucke-Wold
Journal:  Behav Neurol       Date:  2016-12-15       Impact factor: 3.342

6.  The Effect of Oral Administration of Amantadine on Neurological Outcome of Patients With Diffuse Axonal Injury in ICU.

Authors:  Rahman Abbasivash; Mohammad Amin Valizade Hasanloei; Aidin Kazempour; Ata Mahdkhah; Mir Mehdi Shaaf Ghoreishi; Ghazal Akhavan Masoumi
Journal:  J Exp Neurosci       Date:  2019-01-27

7.  Placebo-controlled trial of oral amantadine and zolpidem efficacy on the outcome of patients with acute severe traumatic brain injury and diffuse axonal injury.

Authors:  Sajad Shafiee; Saeed Ehteshami; Mahmood Moosazadeh; Saeed Aghapour; Kaveh Haddadi
Journal:  Caspian J Intern Med       Date:  2022

8.  Prescribing Patterns of Amantadine During Pediatric Inpatient Rehabilitation After Traumatic Brain Injury: A Multicentered Retrospective Review From the Pediatric Brain Injury Consortium.

Authors:  Matthew J McLaughlin; Eric Caliendo; Ryan Lowder; William D Watson; Brad Kurowski; Katherine T Baum; Laura S Blackwell; Christine H Koterba; Kristen R Hoskinson; Sarah J Tlustos; Kanecia O Zimmerman; Sudhin A Shah; Stacy J Suskauer
Journal:  J Head Trauma Rehabil       Date:  2021-07-26       Impact factor: 3.117

9.  A double-blind, placebo-controlled intervention trial of 3 and 10 mg sublingual melatonin for post-concussion syndrome in youths (PLAYGAME): study protocol for a randomized controlled trial.

Authors:  Karen M Barlow; Brian L Brooks; Frank P MacMaster; Adam Kirton; Trevor Seeger; Michael Esser; Susan Crawford; Alberto Nettel-Aguirre; Roger Zemek; Mikrogianakis Angelo; Valerie Kirk; Carolyn A Emery; David Johnson; Michael D Hill; Jeff Buchhalter; Brenda Turley; Lawrence Richer; Robert Platt; Jamie Hutchison; Deborah Dewey
Journal:  Trials       Date:  2014-07-07       Impact factor: 2.279

Review 10.  Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials.

Authors:  Wojciech Danysz; Andrzej Dekundy; Astrid Scheschonka; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2021-02-23       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.